💰 Financial Performance

Profitability Margins

Net loss for the half-year ended September 30, 2025, was INR 67.79 Lakhs, an increase of 17.81% compared to the INR 57.54 Lakhs loss in the previous year's corresponding period. However, the annual loss narrowed by 89.47% from INR 804.10 Lakhs in FY24 to INR 84.64 Lakhs in FY25.

EBITDA Margin

Operating profit before working capital changes was negative INR 70.49 Lakhs for the half-year ended September 30, 2025, indicating that core operations are currently not generating positive cash flow.

Credit Rating & Borrowing

Non-current borrowings increased by 272% to INR 93.00 Lakhs as of September 30, 2025, from INR 25.00 Lakhs as of March 31, 2025. Finance costs for the half-year were INR 0.15 Lakhs.

⚙️ Operational Drivers

Manufacturing Efficiency

Operating profit before working capital changes was negative INR 70.49 Lakhs, indicating that current production levels or pricing are insufficient to cover operating costs.

📈 Strategic Growth

Growth Strategy

The company is undergoing a strategic rebranding to 'Ortin Global Limited' to potentially expand its market reach. The Audit Committee is also mandated to review the rationale and cost-benefits of any mergers or demergers to drive future growth.

Products & Services

Pharmaceutical formulations and laboratory services (formerly Ortin Laboratories Limited).

Market Expansion

The name change to Ortin Global Limited suggests a plan to expand into international markets, though specific regions and timelines are not disclosed.

🌍 External Factors

Industry Trends

The pharmaceutical industry is seeing a shift towards global integration. Ortin is positioning itself through a name change to 'Global' to align with these trends, despite current financial headwinds.

⚖️ Regulatory & Governance

Industry Regulations

Operations are subject to pharmaceutical manufacturing standards and SEBI/Companies Act regulations. Compliance is essential to avoid legal penalties that could strain the company's limited equity of INR 1.30 Cr.

⚠️ Risk Analysis

Key Uncertainties

The primary risk is the continued erosion of equity, with 'Other Equity' standing at negative INR 6.83 Cr, and the ability to service the 272% increase in borrowings.

Credit & Counterparty Risk

Trade receivables decreased by INR 3.60 Lakhs, indicating a small but active collection cycle.